Stanford Jhee

Summary

Affiliation: California Clinical Trials
Country: USA

Publications

  1. ncbi Beta-amyloid therapies in Alzheimer's disease
    S Jhee
    California Clinical Trials Ingenix Pharmaceutical Services, 8501 Wilshire Blvd, Beverly Hills, CA 90211, USA
    Expert Opin Investig Drugs 10:593-605. 2001
  2. ncbi Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review
    S S Jhee
    California Clinical Trials, Beverly Hills 90211, USA
    Clin Pharmacokinet 40:189-205. 2001
  3. ncbi Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol
    Stanford S Jhee
    California Clinical Trials Medical Group, Glendale, CA 91206 4007, USA
    Ann Pharmacother 37:1434-7. 2003
  4. ncbi Cerebrospinal fluid beta-amyloid and dynabridging in Alzheimer's disease drug development
    Larry Ereshefsky
    California Clinical Trials, a division of PAREXEL International, 1560 E Chevy Chase Drive, Suite 140, Glendale, CA 91206, USA
    Biomark Med 3:711-21. 2009
  5. ncbi Antidepressant drug-drug interaction profile update
    Larry Ereshefsky
    University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Drugs R D 6:323-36. 2005
  6. ncbi Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa
    Edyta J Frackiewicz
    Briston Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
    Ann Pharmacother 36:225-30. 2002

Detail Information

Publications6

  1. ncbi Beta-amyloid therapies in Alzheimer's disease
    S Jhee
    California Clinical Trials Ingenix Pharmaceutical Services, 8501 Wilshire Blvd, Beverly Hills, CA 90211, USA
    Expert Opin Investig Drugs 10:593-605. 2001
    ....
  2. ncbi Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review
    S S Jhee
    California Clinical Trials, Beverly Hills 90211, USA
    Clin Pharmacokinet 40:189-205. 2001
    ..Finally, the performance of the triptans is considered in the context of direct head-to-head comparative trials that have assessed the efficacy profile of the compounds...
  3. ncbi Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol
    Stanford S Jhee
    California Clinical Trials Medical Group, Glendale, CA 91206 4007, USA
    Ann Pharmacother 37:1434-7. 2003
    ..To report a case of delayed-onset dystonic reactions, oculogyric crisis (OGC), and torticollis after treatment with intramuscular haloperidol lactate injection...
  4. ncbi Cerebrospinal fluid beta-amyloid and dynabridging in Alzheimer's disease drug development
    Larry Ereshefsky
    California Clinical Trials, a division of PAREXEL International, 1560 E Chevy Chase Drive, Suite 140, Glendale, CA 91206, USA
    Biomark Med 3:711-21. 2009
    ..Corroborative approaches using multiple biomarker methods including neuroimaging and CSF biomarkers will provide a complete picture of the Alzheimer's disease brain...
  5. ncbi Antidepressant drug-drug interaction profile update
    Larry Ereshefsky
    University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Drugs R D 6:323-36. 2005
    ....
  6. ncbi Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa
    Edyta J Frackiewicz
    Briston Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
    Ann Pharmacother 36:225-30. 2002
    ..To investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of the dopamine transporter antagonist brasofensine (BMS-204756) in patients with Parkinson's disease receiving levodopa/carbidopa treatment...